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MCF-7
MDST8A novel library of 15 compounds, hydroxyamides and amides containing a b-D-glucopyranose (D-Gluc) or
a b-D-fructose (D-Fruc) units was designed and synthesized for antiproliferative assays in breast (MCF-7)
and colon (MDST8) cancer cell lines. Twelve of them were hydroxyamides and were successfully synthe-
sized from b-D-glucuronic acid (D-GluA). Six of these hydroxyamides which were acetylated hydroxy-b-D-
glucopyranuronamide 2a–2f (1st Family) and the other six were their respective isomers, that is,
hydroxy-b-D-fructuronamide 3a–3f (2nd Family), obtained by acid–base catalyzed isomerization. These
compounds have the general structure, D-GlucAC@ONHACHRA(CH2)nAOH and D-FrucAC@ONHACHRA
(CH2)nAOH, where R = an aromatic, alkyl or a hydrogen substituent, with n = 0 or 1. Eight of these con-
tained a chiral aminoalcohol group. Three compounds were amides containing a D-glucopyranose unit
(3rd Family). SAR studies were conducted with these compounds. Antiproliferative studies showed that
compound 4a, the bromo-amide containing the b-D-glucopyranose ring, potently inhibits the prolifera-
tion of the MDST8 cells. Five compounds (2e, 2f, 3d, 3e, and 3f) were shown to potently selectively inhibit
the proliferation of the MCF-7 cells. Compound 4b was the only one showing inhibition in both cell lines.
In general, the more active compounds were the amides and hydroxyamides containing the b-D-fructose
moiety, and containing an alkyl group or hydrogen. Half-inhibitory concentrations (IC50) of between 0.01
and 10 lM, were observed.
 2015 Elsevier Ltd. All rights reserved.Cancer is currently one of the most lethal diseases in the world.
Chemotherapy is the most common treatment used for this dis-
ease, which is usually integrated with surgery and radiation ther-
apy. For this reason cancer drug discovery is extremely
important. Carbohydrates are one of the most abundant biomole-
cules on our planet, and currently carbohydrate scaffolds are being
developed for new drugs, as they are intricately involved in inter-
and intracellular communication processes.1 Synthetic and natural
compounds containing the D-glucuronic acid unit have wide rang-
ing pharmacological activities, that include antibiotic, antiviral,
antibacterial and antitumoral activity. Gougerotin, Bagougeramine
A and B are some examples2 of biologically active compounds con-
taining a 4-amido-glucuronamide motif. b-Glucuronides are used
like prodrugs for selective cancer chemotherapy, the active
drug is released by the action of endogenous intracellularb-glucuronidase enzymes (they show elevated concentrations in
tumors compared to normal tissues), and this reduces the toxicity
of the chemotherapy process.3 Recently, El-Nezhawy et al.4 synthe-
sized and evaluated antitumoral activity of some novel acetylated
and deacetylated D-glucuronic acid derivatives and screened them
for antitumor activity using MCF-7, TK-10 and UACC-62 cell lines.
Although a molecular target was not indicated, these studies
revealed some promising compounds for human breast adenocar-
cinoma (MCF-7) growth inhibition such as N-(pyridine-4-yl)-
1,2,3,4-tetra-O-acetyl-b-D-glucopyranuronamide (A) and allyl
1,2,3,4-tetra-O-acetyl-b-D-glucopyranuronate (B) (Fig. 1). Hydrox-
amic acid derivatives play a very important role in cancer therapy,
they are known to be inhibitors of histone deacetylases (HDACs).5
For example, suberanilohydroxamic acid – SAHA (vorinostat)
(Fig. 1) is one of most clinically advanced HDAC inhibitors.6 A large
number of preclinical studies demonstrate that SAHA can induce
growth arrest, differentiation and apoptosis in a wide range of can-
cer cell lines by re-expression of genes (i.e., thioredoxin-binding
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Figure 1. Some compounds with anticancer activity.
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OH), which coordinates with Zn and can also form hydrogen bonds
with the amino acids residues of the HDAC active site, containing
the triad; Tyr306, His142, His143.8 The IC50 value obtained for
SAHA against MCF-7 was 2.5 lM.9
Fructose derivatives also have an important biological applica-
tion, such as for fructose transporter GLUT510 inhibition and anti-
convulsant activity. Fluorescent fructose derivatives were used as
diagnostic reagents for breast cancer.11 Based on recent research,
the overexpression of GLUT5 is an intrinsic characteristic of some
breast cancer cell lines, but not for normal tissue.12 This selective
expression could represent a potential therapeutic target. A few
examples of the successful application of this concept, employing
selective uptake of fructose analogues 6-deoxy-6-fluoro-D-fructose
(C) (Fig. 1)11a and their phosphorescent metal complexes have
appeared in the literature.13 Most workers in this field synthesize
these fructose analogues by isomerization of glucose. Various
methods have been described, such as with enzymes,14 Lewis
acids,15 zeolites16 and ion-exchange resins.17
Our goal was to synthesize three novel families, two of which
consisted of hydroxyamide derivatives of D-glucuronic acid, 1st
Family (compounds 2a–2f) and the 2nd Family (compounds 3a–
3f). The 3rd Family (compounds 4a–4c) was composed of amide
derivatives of D-glucuronic acid containing a bromo or pyrrolidine
ring on the amide tether (Fig. 2). We decided to introduce pyrro-
lidine rings into these molecules given that this unit behaves gen-
erally as an important biostere, present in many molecules active
against cancer.18 Our molecules were designed based on the two
biomolecular targets described above. In the case of HDAC inhibi-
tion, the hydroxyamide and amide attached to the glucopyranose
unit, the –OH and –NH– were designed to function like a zinc-
binding group, forming a H-bond with key H-bonding amino acid
residues in the active site. In the case of the fructose derivatives,
they were designed as GLUT5 transporter inhibitors. The fructose
analogues are expected to be recognized by the GLUT5 receptor
and the hydroxyl groups important for H-bonding and binding in
the central cavity.19 The hydroxyl group is crucial for establishing
H-bonds in the active site of the potentials biological targets, thus
improving the compounds inhibitory effect and consequently its
antitumor activity. Eight of the 12 compounds in our library have
a stereogenic center in the hydroxyamide side chain group. These
molecules were evaluated in antiproliferative tests in the human
breast adenocarcinoma (MCF-7) and colon adenocarcinoma
(MDST8) cell lines. 5-Fluorouracil (5-FU), which is an antineoplasic
agent, was used as a bench-mark.
The 1st and 3rd Families of compounds 2a–2f and 4a–4c,
respectively, were successfully synthesized according to the
general procedure reported in Scheme 1. Compound 1, 1,2,3,4-tetra-O-acetyl-b-D-glucopyranuronic acetic anhydride was syn-
thesized from commercial D-glucuronic acid by treating it with
AcO2/I2 using the method described by Tosin and Murphy.20 Using
the method initially developed by El-Nezhawy et al.,4 compound 1
was reacted with the hydroxyamines I.a–f or amines II.a–c furnish-
ing the corresponding amidoalcohols 2a–2f and amides 4a–4c, in
very good yields, between 24% and 85%. The structure of the com-
pounds 2a–2f and 4a–4c, was confirmed by NMR spectroscopy.
1H NMR analysis confirmed the structures of all the acetylated
compounds 2a–2f and 4a–4c, in general for all compounds, the
anomeric proton appears as a doublet around 5.70 ppm (J = 8 Hz)
which corresponds to the diaxial orientation for both the anomeric
proton and the adjacent proton (H-2), thus confirming the
b-anomeric configuration.
13C NMR was used also to characterize the acetylated
compounds. These compounds were characterized by a signal
at 91.2 ppm corresponding to the anomeric carbon of the
b-D-glucopyranose ring.
The second Family, was synthesized by isomerization of com-
pounds 2a–2f, (Scheme 2) using NaOMe to deprotect the acetyl
groups and at the same time opening the pyran ring to form the
aldose (1st step) or the enolate. The proposed mechanism is
depicted in Scheme 3. The strong acid resin (H+), Amberlite
IR120, was used for ionic exchange of the Na+ with H+, further
keto-enol tautomerism to form the ketone followed by cyclization
onto the ketone (2nd Step) was proposed to give 3c.
NMR studies were conducted to probe the reaction mechanism.
Compound 2c was dissolved in MeOD and NaOMe (5.5 equiv) and
analyzed by 1H NMR. After 30 min a strong signal at 10 ppm
appeared indicating the presence of the aldehyde or enolate (as
the base could probably form the enolate under these conditions).
Amberlite IR120 (H+) was then added, analysis by 1H NMR
showed the presence of a mixture of anomers, consisting of 80%
b-D-fructose and 20% of a-D-fructose with the presence of a vesti-
gial quantity of D-glucopyranose isomers. We used anhydrous con-
ditions to avoid amide hydrolysis. The isomerization of compounds
2a–f also showed an 8:2 mixture of the b/a anomers by 1H NMR
spectroscopy.
All our compounds were evaluated for their antiproliferative
activity against two cell lines, human breast adenocarcinoma
(MCF-7) and human colon adenocarcinoma (MDST8). Batches of
cells were cultured for 72 h with the compounds in the concentra-
tion range of 1  109–1  105 M. Cell proliferation was deter-
mined using Cell Counting Kit (Sigma). 5-FU was used as positive
control for both cell lines. Whenever possible the IC50 values, cor-
responding to a 50% inhibition of proliferation, were determined by
fitting the results to a dose–response growth sigmoidal curve using
Origin Software (OriginLab Corporation). The antiproliferative
results are representative of n = 2–3 independent experiments
with 5 replicates each. 5-FU showed IC50 values of 6.4  108 M
and 5.2  107 M for MDST8 and MCF-7, respectively (data not
shown). At the highest concentration used, 1  105 M, 5-FU inhib-
ited colon and breast cell growth by 83 and 60%, respectively
(Fig. 3).
Antiproliferative activity at a concentration of 1  108 M (50%
of inhibition) in the MDST8 cell line was only observed in the case
of 4a containing a Br, this compound had more than 90% of an
antiproliferative effect at 1  105 M, and was more active than
5-FU Hydroxy-D-fructuronamide derivative 3c with an isopropyl
substituent, had 80% of an antiproliferative effect at 1  105 M
against MDST8 cell line, and was more active than its isomer 2c.
Compound 3d had an antiproliferative effect in the MCF-7 cell line
and showed similar inhibition as 5-FU. In the case of those com-
pounds with aromatic substituents, like 2a and 3a (benzyl) and
2b and 3b (phenyl), they didn’t show any antiproliferative activity
in the MDST8 and MCF-7 cell lines. 2e–f and 3e–f, were shown to
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Scheme 1. Synthesis of acetylated hydroxy-b-D-glucopyranuronamide 2a–2f (1st family) and b-D-glucopyranuronamide 4a–4c (3rd family).
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Figure 2. Libraries of novel hydroxyamide and amides derivatives derived from D-glucuronic acid.
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line, these four compounds inhibited the cell proliferation by more
than 60%, and were also more effective than 5-FU. 3f exhibited
more antiproliferative activity at 1  105 M concentration. These
compounds were inactive against the MDST8 cell line. The
hydroxy-D-fructuronamides (2nd Family), showed similar antipro-
liferative effects as their respective acetylated isomers. This could
be explained on the basis of a rather narrow dynamic range for
these compounds that is probably related with their mechanism
of action. Compounds 2e and 2f are expected to dissolve in the
lipid bilayer, and are likely to disturb membrane function. The lipid
environment in each cell line may influence the degree of accumu-
lation of the inhibitors in the plasma membrane, hence the differ-
ential effects observed. Compounds 3d, 3e and 3f contain a
fructose-like ring that is too polar to permeate the lipid bilayerbut because of this structural motif are potential inhibitors of the
GLUT5 receptor which is overexpressed by MCF-712 but not as
much by the MDST-8 cell line. To assess the dose-dependent effect,
tests using a different range of concentrations would be necessary.
In the case of the 3rd Family, the amide derivatives containing a
pyrrolidine unit, that is, 4b and 4c, compound 4b was shown to be
active in the both cell lines, but more active in the MCF-7 cell line
with an IC50 of 1  106 M. Bis-amide compound 4c was only
active in the MDST8 cell line with an IC50 of 1  107 M.
It is likely that the acetylated compounds used in this study suf-
fer cleavage of their labile ester group inside the cell due to the
action of esterases or other hydrolytic agents, making them more
bio-active entities, probably via stronger interactions with
the HDACs through H-bonding. Compounds (4a–4c) inhibited
proliferation of both cell lines but were more effective for MDST8.
Figure 3. Graphical representation of the anti-proliferative results obtained against the MDST8 and MCF-7 cell lines. 5-FU was used at 1  105 M as a positive control. Data
are presented as means ± SD (⁄significant for P < 0.05).
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and 10 lM, similar to those for the medicinal compounds A and
B shown in Fig. 1.
A structure–activity relationship (SAR) was observed for fifteen
of our compounds. For the hydroxyamides containing benzyl and
phenyl units (1st and 2nd families; 2a, 2b, 3a and 3b) low activity
in both cell lines was observed, and there was no significant
enhancement in activity on changing the structure of the sugarfrom glucose to fructose. The antiproliferative activity in both
cell-lines was enhanced on changing the aromatic unit for an alkyl
substituent (3c and 3d) in this group. Compound 3c containing an
isopropyl unit showed an antiproliferative effect only against the
MDST8 cell line and the tert-butyl containing analogue 3d was
selective for only the MCF-7 cell line. The hydroxy-b-D-glucopyra-
nuronamides 2e–2f and the hydroxy-b-D-fructuronamides 3e and
3f containing a non-substituted linear amide side-chain, were
E. P. Carreiro et al. / Bioorg. Med. Chem. Lett. 26 (2016) 1039–1043 1043active and selective for only the MCF-7 cell line. On the contrary,
compound 4a, containing a bromo-substituted linear amide side-
chain, was active for the MDST8 cell line but inactive in the MCF-
7 cell line. Indicating that the OH group is important in MCF-7
antiproliferative activity. The effect of the OH in the amide side-
chain on the activity of the molecule was enhanced by increasing
the side-chain length (compare those analogues containing ethyl
(2e and 3e) and propyl (2f and 3f) chains in the amide unit). Com-
pound 4b containing a pyrrolidinyl substituent was shown to be
the most active inhibitor against MCF-7.
In conclusion, we synthesized three new families of hydrox-
yamides and amides derived from D-glucuronic acid, using simple
but efficient synthetic methods. Their antiproliferative activity
against two cancer cell lines, MDST8 and MCF-7, were studied
and some showed good antiproliferative activity. Compounds 2e,
2f, 3d, 3e, 3f and 4b were shown to be active against MCF-7, with
an anti-proliferative effect in the 1 lM to 10 lM concentration
range. Compounds 3c, 4a, 4b and 4c were shown to be active
against MDST8. The amide derivatives exhibited a stronger
antiproliferative effect than the hydroxyamides, in both families
(against MDST8). Compound 4a was selective for MDST8 and the
best inhibitor having an IC50 of 100 nM. Compound 4a containing
a 3-bromopropyl amide side-chain gave the best results for this
cell line. In the case of the MCF-7 cell-line, hydroxyamide com-
pounds (2e, 2f, 3d, 3e, 3f) were generally more active than the
amide derivatives (4a–4c), however the lowest IC50 was obtained
for 4b (1 lM). On comparing the activity of our compounds with
5-FU, some showed better biological activity than 5-FU. 4a and
4c presented better activity than this bench-mark compound
against the MDST8 cell line. With regard to the MCF-7 cell line,
compounds 2e, 2f, 3f showed better activity than 5-FU. These fam-
ilies of b-D-glucopyranose and b-D-fructose derivatives appear to
be promising candidates for inhibiting both MDST8 and MCF-7 cell
lines. Further studies are continuing at developing more potent
analogues for these cell-lines and at probing their molecular target.
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